SRD5A1-IN-1 (Compound 4) is a competitive and covalent steroid 5α-reductase type 1 (SRD5A1) inhibitor with an IC50 of 1.44 µM. SRD5A1-IN-1 modulates SRD5A1 function, leading to a lower level of dihydrotestosterone (DHT) production and SRD5A1 protein suppression.
SRD5A1-IN-1 (Compound 4) (0.5-2.5 μM; 24 h) decreases SRD5A1 protein expression[1].
SRD5A1-IN-1 (0-2.5 μM; 12 h) modulates SRD5A1 via the dual actions that affect the level of SRD5A1 protein expression and the activity of the SRD5A1 enzyme[1].
References:
[1]. Lin A C K, et al. Caffeic acid N-[3, 5-bis (trifluoromethyl) phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics. Scientific Reports, 2022, 12(1): 1-20.